SCHEMBL17480640

SCHEMBL17480640

CCc1sc(C(C)C)nc1C(C)C

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17480642 0.78
SCHEMBL20909366 0.78 NPC1 (0.38)
SCHEMBL10129942 0.78 NMT1 (0.32)
SCHEMBL17481211 0.78 GRM5 (0.34)
SCHEMBL27356687 0.77 TLR8 (0.36)
SCHEMBL26973679 0.77
SCHEMBL14016161 0.77 L3MBTL1 (0.30)
SCHEMBL24599943 0.74
SCHEMBL10130048 0.74
SCHEMBL10129936 0.74

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2024039901-A2 CDK2 DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. (US) 2024-02-22 WO disclosed
US-20240018102-A1 COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH LPA RECEPTOR ACTIVITY Lhotse Bio, Inc (US) 2024-01-18 US disclosed
US-20210214323-A1 NOVEL COMPOUNDS AND COMPOSITIONS FOR INHIBITION OF FASN FORMA THERAPEUTICS, INC. 2021-07-15 US disclosed
US-20200222400-A1 METHODS FOR THE TREATMENT OF NEUROLOGICAL DISORDERS JANSSEN PHARMACEUTICA NV (BE) 2020-07-16 US disclosed
US-20170015671-A1 INHIBITORS OF BRUTON'S TYROSINE KINASE PHARMACYCLICS LLC 2017-01-19 US disclosed
US-9533991-B2 Inhibitors of Bruton's tyrosine kinase PHARMACYCLICS LLC (US) 2017-01-03 US disclosed
US-20160031891-A1 INHIBITORS OF BRUTON'S TYROSINE KINASE PHARMACYCLICS LLC 2016-02-04 US disclosed